CAR-T

Four oncology treatment advances to watch
Four oncology treatment advances to watchExperts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
Ten ways multiple myeloma treatment is changingAs multiple myeloma treatment improvements continue, it’s important for managed care executives to get out in front of these 10 changes on the horizon.
Tisagenlecleucel (Kymriah) for Acute Lymphoblastic Leukemia
Tisagenlecleucel (Kymriah) for Acute Lymphoblastic LeukemiaA new era of treatment has arrived—here’s what you need to know.
Payers struggle to keep up with high rate of FDA drug approvalsFDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
Game-changing gene therapies present cost problems for health execsCAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.
Four ways health execs can prep for costly CAR-T cell therapiesWith the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.
This is why you should be excited for upcoming cancer researchAcute myeloid leukemia experts share promising new developments on the oncology horizon.
FDA Approves First Gene TherapyWhy the agency says the approval of Novartis’ new therapy is historic.